Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Electrum Identifies New Mineralised Trends and Refines Targeting with Magnetic Survey (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cipher Pharmaceuticals Inc
T.CPH
Alternate Symbol(s):
CPHRF
Healthcare
Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology...
products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
(99)
•••
Northforce13
X
Comment by
Northforce13
on Dec 02, 2021 10:59am
RE:RE:4 Quarter Trends in Absorica and Absorica +
"I expect about 1.5 cent per quarter gain in EPS due to this factor." - Might want to check your math, maybe you meant 0.15 c/quarter... It's not much of a factor, but it
...more
(4967)
•••
nozzpack
X
Comment by
nozzpack
on Dec 02, 2021 10:01am
RE:4 Quarter Trends in Absorica and Absorica +
When I look over all of this, I see Q4 being about the same level it was in Q4 of 2020 which is $6 million US. In addition, leasing its office space ( which cost us for inducement $2.2 million
...more
(99)
•••
Northforce13
X
Comment by
Northforce13
on Dec 02, 2021 9:40am
RE:4 Quarter Trends in Absorica and Absorica +
Interesting
(4967)
•••
nozzpack
X
Post by
nozzpack
on Dec 02, 2021 9:32am
4 Quarter Trends in Absorica and Absorica +
Entering 2021, Absorica market share in the US was 5.5 % and 7 % for 2020. Q1 and Q2 are weaker quarters in the US due to patients having to pay off their share of drug costs. By Q3, some patients
...more
(4967)
•••
nozzpack
X
Comment by
nozzpack
on Dec 02, 2021 8:52am
RE:RE:RE:Isotrentoin Market in US had 17.8 % Growth 2021
Now I understand the agreement. Royalties on all three absorica products until 2024. However, CPH will be able to issue a NDA fpr isotrention as of November 2022. That implies that CPH can launch
...more
(4967)
•••
nozzpack
X
Comment by
nozzpack
on Dec 01, 2021 4:50pm
RE:RE:Isotrentoin Market in US had 17.8 % Growth 2021
In July 2018, the Company amended its distribution and supply agreement [the “Sun Amendment”] with Sun for Absorica. The Sun Amendment provides Sun with the ability to launch new isotretinoin
...more
(99)
•••
Northforce13
X
Comment by
Northforce13
on Dec 01, 2021 10:35am
RE:Isotrentoin Market in US had 17.8 % Growth 2021
"Am I not correct that all Absorica formulations sold by Teva in the US reverts to Cipher in November 2022 ?" I haven't read anything about that, or perhaps did but didn't pay it
...more
(4967)
•••
nozzpack
X
Post by
nozzpack
on Dec 01, 2021 8:11am
Isotrentoin Market in US had 17.8 % Growth 2021
According to Symphony Health, the U.S. isotretinoin prescription market increased by 17.8% in the nine-month period ended September 30, 2021 compared to the nine-month period ended September 30, 2020.
...more
(0)
•••
whatifidont
X
Comment by
whatifidont
on Nov 30, 2021 10:38am
RE:RE:Here we go
I bought more, I think it's just market fear
(99)
•••
Northforce13
X
Comment by
Northforce13
on Nov 29, 2021 4:23pm
RE:Here we go
Dunno lol! Never thought I'd see it at these prices. At this rate we could be back to 1.00 by year end ;-) Bought a bit more at 1.75 in my TFSA I have been toying with the idea of
...more
(0)
•••
Rsoleblocka
X
Post by
Rsoleblocka
on Nov 29, 2021 4:16pm
just a bit bitter
woulda coulda shoulda......i shall remain optomistic!
(4967)
•••
nozzpack
X
Comment by
nozzpack
on Nov 29, 2021 4:09pm
RE:RE:Here we go
It's the sheeple getting spooked. Nice to see those shares being bought back..
(192)
•••
Daudau11
X
Comment by
Daudau11
on Nov 29, 2021 2:08pm
RE:Here we go
I hope so I have a bid near that price and I want to get filled!!
(0)
•••
Rsoleblocka
X
Post by
Rsoleblocka
on Nov 29, 2021 12:37pm
Here we go
Will it hit 1.50 this week?
(0)
•••
Rsoleblocka
X
Post by
Rsoleblocka
on Nov 29, 2021 12:15pm
I blew it
If this ever hits 2 I am out.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Graphite One and Lucid Enter into Second Non-Binding Supply Agreement
Graphite Creek Project Approved for FAST-41 Federal Permitting Dashboard
Mullen Group acquires company expected to generate annualized revenues of $300 million
Despite turbulent markets this logistics company continues to grow
Merger Announced to Create a Leading Yukon Copper-Gold Exploration and Development Company
New Analyst Report Lifts Almonty Target Price to CDN$5.50